Handelsavisen
prelaunch
Companies Healthcare 420570.KQ
42
420570.KQ KOSDAQ Pharmaceuticals

420570.Kq

$7 700,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
3,03 %
Op margin
8,8 %
ROE
7,9 %
Net margin
8,1 %
Debt / equity
0,03
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and related healthcare services.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and related healthcare services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
7,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 420570.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 420570.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products and medical research, generating revenue primarily through the sale of its drug formulations and related healthcare services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a strong capital structure, with a debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing and a robust equity base. Its liquidity position is characterized by a current ratio of 7.09, suggesting ample short-term assets to cover liabilities. However, the risk assessment notes a medium liquidity risk, with net cash being negative after subtracting total debt, which could signal potential short-term cash flow constraints.

    Profitability metrics show a return on equity (ROE) of 7.91% and a return on assets (ROA) of 7.02%, both of which are strong indicators of efficient asset utilization and profitability. These figures are in line with the industry's preferred metrics, suggesting the company is performing at or above the median for its sector.

    The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could pose a concentration risk, as the company's performance is tied to a single operational area.

    Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. Historical revenue data and the absence of a forecasted change suggest a conservative outlook, with the company likely to continue its current operational pace.

    Risk factors include a medium liquidity risk and a low dilution potential, with no significant dilution sources identified in the available data. The company's capital structure remains stable, with no recent events indicating a need for equity issuance or debt restructuring.

    Recent events, including filings and transcripts, are not detailed in the available data, but the company's financial health and operational stability suggest a low likelihood of material adverse events in the near term. The absence of recent dilutive events supports the low dilution risk assessment.

    Key takeaways
    • The company has a strong equity base and a low debt-to-equity ratio, indicating a conservative capital structure.
    • Profitability metrics are robust, with ROE and ROA exceeding the industry median.
    • The company's revenue is concentrated in a single segment, which could increase exposure to sector-specific risks.
    • Liquidity risk is moderate, with a current ratio of 7.09 but a negative net cash position after debt.
    • No significant dilution risk is present, and the company's capital structure remains stable.
    • The company is expected to maintain a stable growth trajectory with no significant changes in revenue forecasted.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $7 700,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $33.77B
    Net cash
    -$1.13B
    Current ratio
    7.1
    Debt / equity
    0.0
    ROA
    7.0%
    ROE
    7.9%
    Cash conversion
    76.0%
    CapEx / revenue
    -3.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,8 %Above median
    Net Margin8,1 %Above median
    ROE7,9 %Above median
    Capex / Rev-3,5 %Above median
    D/E0,03Above median
    Cash Conv0,76Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 420570.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    420570.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage